We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Stem Cell Therapy Restores Youthful Heart Performance

By LabMedica International staff writers
Posted on 24 Aug 2017
Cardiac disease researchers have demonstrated in a rat model that injections of cardiosphere-derived cells from young rats could rejuvenate the hearts of aged animals.

Investigators at Cedars-Sinai Heart Institute (Los Angeles, CA, USA) worked with cardiosphere-derived cells (CDCs) provided by the biotechnology company Capricor Inc. More...
(Beverly Hills, CA, USA).

Cardiospheres (CSps) are clusters of stem cells obtained from heart muscle, while cardiosphere-derived cells (CDCs) are CSp cells that have been formatted into a single layer. CDCs possess regenerative properties, which are expressed not by becoming part of the recipient’s heart, but by acting at a distance to cause cells in the recipient heart to divide and/or differentiate. CDCs in doses sufficient for activity can be injected into the coronary arteries without damaging the heart muscle. Since CDCs originate in the myocardial cell lineage, they are particularly well-suited to stimulate the heart’s innate restorative capabilities.

While the heart muscle appears capable of healing from daily “wear and tear,” its repair systems are insufficient to address extensive damage such as that which results either from an acute event, such as a heart attack, or from chronic injury, which may be associated with a variety of conditions. Following their infusion, CDCs track to the area of injury and release growth factors and cytokines that signal the heart to repair itself. Although the infused CDCs are eventually cleared from the body, their beneficial effects are believed to be long-lasting.

In the current study, the investigators injected CDCs from newborn rats into the hearts of rats with an average age of 22 months, which is considered aged. A control group of aged animals received a placebo treatment, saline injections instead of stem cells. Heart responses of both groups of aged rats were compared to a group of young rats with an average age of four months. Baseline heart function was measured in all rats, using echocardiograms, treadmill stress tests, and blood analysis.

Results published in the August 14, 2017, online edition of the European Heart Journal revealed that CDCs, but not PBS, restored a youthful pattern of gene expression in the hearts of old animals, and telomeres in heart cells were longer in CDC-transplanted animals. In addition, the animals receiving CDCs experienced improved heart function, enhanced their exercise capacity by an average of approximately 20%, regrew hair faster, and showed reduced levels of serum biomarkers of inflammation (IL-10, IL-1b, and IL-6).

"Our previous lab studies and human clinical trials have shown promise in treating heart failure using cardiac stem cell infusions," said senior author Dr. Eduardo Marbán, director of the Cedars-Sinai Heart Institute. "Now we find that these specialized stem cells could turn out to reverse problems associated with aging of the heart. The way the cells work to reverse aging is fascinating. They secrete tiny vesicles that are chock-full of signaling molecules such as RNA and proteins. The vesicles from young cells appear to contain all the needed instructions to turn back the clock."

Related Links:
Cedars-Sinai Heart Institute
Capricor


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
PSA Assay
CanAg PSA EIA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.